Preliminary results of using ALAnerv® in subacute motor incomplete paraplegics.
BACKGROUND
To assess whether using ALAnerv® contributes to improvements of outcomes obtained in post SCI patients.


OBJECTIVE
A prospective controlled clinical survey also to evaluate the safety and efficacy of ALAnerv® (2cps/ day for 28 days) in motor incomplete (AIS/ Frankel C) paraplegic subacute patients.


RESULTS
59 patients divided in study (treated with ALAnerv®) and control, groups. This survey's follow-up duration was of 28 days. Most of the studied patients were mid-aged (mean 43.75 years old) and respectively, men (64,29% in the study group; 58,06% in controls). We used descriptive statistics (functions: minimum, maximum, mean, median, standard deviation) and for related comparisons, parametric (Student t) and non-parametric (Mann-Whitney, Fisher's exact, chi-square) tests. The primary end-point: AIS motor values' evolution (P= 0.015 - Mann-Whitney), showed that patients treated with ALAnerv® - vs. controls - had a statistically significant better increase of such scores at discharge. Paraclinical parameters, mainly exploring systemic inflammatory status (secondary end-point): ESR dynamics (P=0.13) had no statistical significance; the plasma leucocytes number (P=0.018), the neutrophils' percentage (P=0.001) and fibrinogenemia (P= 0,017) proved in the treated group to have a statistically significant better evolution. We used "Statistical Package for Social Sciences" (SPSS).


CONCLUSIONS
As there is actually no effective curative solution for the devastating pathology following SCI, any medical approach susceptible to bring even limited improvements, such as treatment with ALAnerv® seemed to have proven, is worth being surveyed, under strict circumstances of ethics and research methodology. Considering the necessity for more statistical power concerning primary, secondary end-points, and safety issues, as well, continuing this research is needed.


BACKGROUND
SCI = spinal cord injury, TSCI = traumatic spinal cord injury, BBB = blood brain barrier, CNS = central nervous system, SC = spinal cord, NSAIDs = non-steroidal anti-inflammatory drugs, SAIDs = steroidal anti-inflammatory drugs, AIS = American Spinal Injury Association Impairment Scale, SPSS = Statistical Package for Social Sciences, BATEH = Bagdasar-Arseni Teaching Emergency Hospital.
"Bagdasar Arseni" Teaching Emergency Hospital (BATEH), Bucharest, Romania; "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
I
I
Andone
"Bagdasar Arseni" Teaching Emergency Hospital (BATEH), Bucharest, Romania; "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
A
A
Anghelescu
"Bagdasar Arseni" Teaching Emergency Hospital (BATEH), Bucharest, Romania; "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
C
C
Daia
"Bagdasar Arseni" Teaching Emergency Hospital (BATEH), Bucharest, Romania; "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
G
G
Onose
D017677:Age Distribution; D016022:Case-Control Studies; D019587:Dietary Supplements; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009043:Motor Activity; D010264:Paraplegia / Q000097:blood / Q000503:physiopathology* / Q000628:therapy*; D011446:Prospective Studies; D013119:Spinal Cord Injuries / Q000097:blood / Q000209:etiology
motor incomplete paraplegia; neuroprotection; neurotrophic compound; nutritional supplement